アジア太平洋の過敏性腸症候群治療市場予測:2021-2028

◆英語タイトル:ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028
◆商品コード:INK21MC010
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2021年2月1日
◆ページ数:151
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥142,500見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥171,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Inkwood社の本調査レポートは、アジア太平洋の過敏性腸症候群治療市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別分析、製品別分析、流通チャンネル別分析、作用機序別分析、調剤別分析、地域別分析、競争状況などの情報をお届けいたします。
【レポートの概要】

KEY FINDINGSThe Asia Pacific irritable bowel syndrome treatment market is predicted to project a CAGR of 8.92% during the forecast period, 2021-2028. The primary factors contributing to the market growth include the increasing focus of eminent manufacturers on geographical expansion and the developing R&D sector.

MARKET INSIGHTS
India, Japan, China, Vietnam, Australia & New Zealand, Indonesia, Thailand, South Korea, and Rest of Asia Pacific are analyzed for the Asia Pacific irritable bowel syndrome treatment market growth evaluation. According to a 2019 study, in Japan, the prevalence of functional constipation (FC) and irritable bowel syndrome (IBS-C) was 8.76% and 4.97%, respectively. IBS-C resulted in more symptoms than FC, leading to impairment of quality of life. The increasing life expectancy in the country is set to result in an increased geriatric population. According to the Statistics Bureau, Ministry of Internal Affairs and Communications, the aged population in 2019 constituted around 28% of the total population. Such factors are expected to increase market growth.
In Australia, one in five people has experienced the symptoms of IBS at some point in time. These are mucus in stools, alternating diarrhea, constipation, and abdominal pain. There is an increasingly aging population in the country. As per the Australian Institute of Health and Welfare, the aging population graph is expected to grow further. In New Zealand, IBS is a relatively common condition. At the same time, it is difficult to gauge the numbers due to the low turn up of people for diagnosis. The geriatric population of the country constitutes 15% of the total population as per the Statistics New Zealand. Such factors are evaluated to drive market growth in Australia & New Zealand.

COMPETITIVE INSIGHTS
Some of the key players in the market include, Novartis AG, Lannett Company Inc, Takeda, Pharmaceutical Company Ltd, Synthetic Biologics Inc, Sebela Pharmaceuticals Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1.STUDY OBJECTIVES
1.2.SCOPE OF STUDY
1.3.METHODOLOGY
1.4.ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1.MARKET SIZE & ESTIMATES
2.2.MARKET OVERVIEW
3. MARKET DYNAMICS
3.1.KEY DRIVERS
3.1.1. RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
3.1.2. GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
3.1.3. SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
3.1.4. INCREASING GERIATRIC POPULATION
3.2.KEY RESTRAINTS
3.2.1. HIGH COST OF DRUGS
3.2.2. LACK OF SKILLED PROFESSIONALS IN DEVELOPING ECONOMIES
3.2.3. LIMITED TREATMENT OPTIONS
4. KEY ANALYTICS
4.1.PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2.IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
4.3.OPPORTUNITY MATRIX
4.4.VENDOR LANDSCAPE
4.5.KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1.IBS WITH DIARRHEA
5.2.IBS WITH CONSTIPATION
5.3.MIXED IBS
6. MARKET BY PRODUCT
6.1.RIFAXIMIN
6.2.ELUXADOLINE
6.3.LINACLOTIDE
6.4.LUBIPROSTONE
6.5.OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1.DRUG STORES AND RETAIL PHARMACIES
7.2.HOSPITALS’ PHARMACIES
7.3.ONLINE PHARMACIES
8. MARKET BY MECHANISM OF ACTION
8.1.5HT3 ANTAGONIST
8.2.GUANYLATE CYCLASE RECEPTOR-C AGONIST
8.3.CHLORIDE CHANNEL ACTIVATOR
8.4.OTHER MECHANISM OF ACTIONS
9. MARKET BY DOSAGE
9.1.SOLID
9.2.LIQUID
10. GEOGRAPHICAL ANALYSIS
10.1.ASIA PACIFIC
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. KEY GROWTH ENABLERS
10.1.3. KEY CHALLENGES
10.1.4. KEY PLAYERS
10.1.5. COUNTRY ANALYSIS
10.1.5.1. JAPAN
10.1.5.2. CHINA
10.1.5.3. AUSTRALIA & NEW ZEALAND
10.1.5.4. INDIA
10.1.5.5. SOUTH KOREA
10.1.5.6. THAILAND
10.1.5.7. INDONESIA
10.1.5.8. VIETNAM
10.1.5.9. REST OF ASIA PACIFIC
11. COMPETITIVE LANDSCAPE
11.1.KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGER & ACQUISITIONS
11.1.2. PRODUCT LAUNCH & DEVELOPMENTS
11.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
11.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
11.2.COMPANY PROFILE
11.2.1. ABBOTT LABORATORIES
11.2.2. BAUSCH HEALTH COMPANIES INC
11.2.3. ALLERGAN PLC
11.2.4. ARDELYX INC
11.2.5. ASTELLAS PHARMA INC
11.2.6. ASTRAZENECA PLC
11.2.7. GLAXOSMITHKLINE PLC
11.2.8. IRONWOOD PHARMACEUTICALS INC
11.2.9. JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
11.2.10. LANNETT COMPANY INC
11.2.11. NOVARTIS AG
11.2.12. SEBELA PHARMACEUTICALS INC
11.2.13. SYNTHETIC BIOLOGICS INC
11.2.14. TAKEDA PHARMACEUTICAL COMPANY LTD

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT
TABLE 2: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 14: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020
FIGURE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)
FIGURE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020
FIGURE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020
FIGURE 16: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)
FIGURE 19: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020
FIGURE 20: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)
FIGURE 21: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)
FIGURE 22: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)
FIGURE 23: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)
FIGURE 24: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020
FIGURE 25: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)
FIGURE 26: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)
FIGURE 27: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 28: JAPAN IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 29: CHINA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 30: AUSTRALIA & NEW ZEALAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 31: INDIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 32: SOUTH KOREA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 33: THAILAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 34: INDONESIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 35: VIETNAM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)
FIGURE 36: REST OF ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アジア太平洋の過敏性腸症候群治療市場予測:2021-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆